ClinicalTrials.gg

Program

plonmarlimab

Also written as “Plonmarlimab”, “TJ003234” and “TJ003234 injection”.

Its studies are mostly in Arthritis, Gouty · Lymphohistiocytosis, Hemophagocytic · COVID-19 · Arthritis, Rheumatoid, led by 2 companies.

Furthest: phase 3, since Apr 4, 20206 company-led studies, 2 open or runningNext primary completion: Dec 20, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
I-Mab Biopharma US30 open or runningphase 3since Apr 4, 2020Dec 28, 2018none ahead
TJ Biopharma32 open or runningphase 3since Sep 27, 2025Jun 13, 2025Dec 20, 2026phase 3 · NCT07208058

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 28, 2018First study: phase 1 study in Healthy Adult SubjectsNew to I-Mab Biopharma USI-Mab Biopharma US · NCT03794180 · 32 enrolled · United States
  2. Apr 4, 2020Phase 3 study in Coronavirus Disease 2019 COVID-19I-Mab Biopharma US · NCT04341116 · 149 enrolled · United States
  3. Jun 28, 2020Phase 1 study in Arthritis, RheumatoidI-Mab Biopharma US · NCT04457856 · 63 enrolled · China
  4. Jun 13, 2025TJ Biopharma's first study: phase 2 study in Lymphohistiocytosis, HemophagocyticNew to TJ BiopharmaTJ Biopharma · NCT07034209 · 18 enrolled · China
  5. Sep 27, 2025Phase 3 study in RecurrenceTJ Biopharma · NCT07208058 · 30 planned · China
  6. Feb 27, 2026Phase 2 study in Acute Gouty ArthritisTJ Biopharma · NCT07453004 · 170 planned · China

Ahead

  1. Dec 20, 2026Primary completion: phase 3 study in RecurrenceTJ Biopharma · NCT07208058
  2. Dec 31, 2027Primary completion: phase 2 study in Acute Gouty ArthritisTJ Biopharma · NCT07453004

TargetBeta

CSF2 →read by rule
“A humanized immunoglobulin (Ig) G1 monoclonal antibody against the human cytokine granulocyte macrophage colony-stimulating factor (GM-CSF), ”NCIt, by rule
“Granulocyte-macrophage colony-stimulating factor antagonist”ChEMBL 37, by rule

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07453004Acute Gouty Arthritis · China2RecruitingTJ BiopharmaDec 31, 2027170
NCT07208058Recurrence · China3RecruitingTJ BiopharmaDec 20, 202630
NCT07034209Lymphohistiocytosis, Hemophagocytic · China2CompletedTJ BiopharmaApr 18, 202518
NCT04457856Arthritis, Rheumatoid · China1UNKNOWNI-Mab Biopharma USMar 202363
NCT04341116Coronavirus Disease 2019 COVID-19 · United States3CompletedI-Mab Biopharma USFeb 7, 2022149
NCT03794180Healthy Adult Subjects · United States1CompletedI-Mab Biopharma USSep 5, 201932

How it is read

Names in the registry

  • “Plonmarlimab”, 3 entries
  • “TJ003234”, 2 entries
  • “TJ003234 injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.